Abstract
Background
Gastrointestinal stromal tumours (GISTs), although rare, are increasingly recognized, characterized immuno-phenotypically in most cases by a mutation in C-Kit. The advent of imatinib, a tyrosine kinase inhibitor, has presented a novel and effective therapy in advanced disease. The aim of this study was to present the experience and outcomes of a single centre.
Methods
Review of prospective GIST database at St James Hospital from 1997 to 2005. Survival data were analysed using Kaplan–Meier methods.
Results
A total of 32 patients (19 males/13 females) with a median age of 61 years (10–84) were treated. The stomach (n = 20) was the dominant site. Surgery was the first line of treatment for all these tumours, and in seven cases this was performed laparoscopically. C-Kit was positive in 81% of cases. The median survival was 78 months with a 5-year survival of 71%.
Conclusion
GISTs are rare and surgical resection, increasingly with minimally invasive approaches, is associated with high cure rates, particularly in gastric tumours.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Consensus meeting for the management of gastrointestinal stromal tumours (2005) Report of the GIST consensus conference of 20–21 March 2004, under the auspices of ESMO. Ann Oncol 16(4):566–578
Hirota S, Isozaki K, Moriyama Y et al (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumours. Science 279:577–580
Mazur MT, Clarke HB (1983) Gastric stromal tumours: reappaisel of histogenesis. Am J Surg Pathol 7:507–519
Sircar K, Hewlett BR, Huizinga JD et al (1999) Interstitial cells of Cajal as precursors of gastrointestinal tumours. Am J Surg Pathol 23:377
Miettenen M, Sobin LH, Lasota J (2005) Gastrointestinal stromal tumors of the stomach: a clinicopathological, immunohistochemical and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 29:52–68
Fletcher CDM, Berman JJ, Corless C et al (2002) Diagnosis of gastrointestinal stromal tumours: a consensus approach. Hum Pathol 33:459–465
Demetri GD, von Mehren M, Blanke CD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347(7):472–480
DeMatteo RP (2002) The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571). Ann Surg Oncol 9(9):831–839
Lai IR, Lee WJ, Yu SC (2006) Minimally invasive surgery for gastric stromal cell tumors: intermediate follow-up results. J Gastrointest Surg 10(4):563–566
Connolly EM, Gaffney E, Reynolds JV (2003) Gastrointestinal stromal tumours. Br J Surg 90(10):1178–1186
Iwahashi M, Takifuji k, Ojima T, Nakamura M et al (2006) Surgical management of small gastrointestinal stromal tumours of the stomach. World J Surg 1(30):28–35
DeMatteo RP, Lewis JJ, Leung D et al (2000) Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231(1):51–58
Fujimoto Y, Nakanishi Y, Yoshimura K, Shimoda T (2003) Clinicopathologic study of primary malignant gastrointestinal tumors of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patients. Gastric Cancer 6:39–48
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Butt, J., Rowley, S., Byrne, P.J. et al. Management of gastrointestinal stromal tumours: a single-centre experience. Ir J Med Sci 176, 157–160 (2007). https://doi.org/10.1007/s11845-007-0054-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11845-007-0054-6